MycN Inhibitors

The chemical class known as MycN inhibitors encompasses molecules that can impede the function or expression of the N-Myc protein. Since direct inhibition is not achievable with small molecules due to the structure of N-Myc, indirect strategies are employed. These strategies include the disruption of protein-protein interactions essential for N-Myc's transcriptional activity, alteration of chromatin structure influencing N-Myc gene expression, and interference with signaling pathways upstream or downstream of N-Myc that regulate its stability and function.

Compounds like 10058-F4 are designed to inhibit the dimerization of Myc family proteins, thus affecting N-Myc's ability to regulate gene expression. Bromodomain inhibitors such as JQ1 work by preventing the recognition of acetylated lysines, which is critical for the transcriptional activity of genes like those of the Myc family. Histone deacetylase inhibitors (e.g., Trichostatin A) change the acetylation status of histones, thereby potentially decreasing N-Myc expression. Cell cycle inhibitors such as PD 0332991 (Palbociclib) and LEE011 (Ribociclib) impact the cell cycle, which is a crucial factor in cells where N-Myc is a driving oncogene. Kinase inhibitors like Alisertib (MLN8237) can halt cell division, affecting processes in which N-Myc is a pivotal player. The Exportin 1 inhibitor (KPT-276) may influence the cellular localization and function of N-Myc. Compounds targeting the apoptotic machinery, such as LCL-161 and A-1210477, can modulate the cellular environment to influence the function and regulation of N-Myc. Lastly, CYT387, a JAK inhibitor, can modulate signaling pathways that may cross-talk with those regulated by N-Myc, influencing its activity.